|
|||||||||||||||||||||||||||||||||||||||||||||||
![]()
CAS号:475-31-0
|
英文名称:Glycocholic acid
分子式
C26H43NO6
分子量
466
EINECS号
207-494-9
MDL
MFCD00065902
Smiles
O[C@@H]1C[C@]2([H])C[C@H](O)CC[C@]2(C)[C@@]2([H])C[C@H](O)[C@@]3([C@@]([H])([C@H](C)CCC(=O)NCC(=O)O)CC[C@@]3([H])[C@]12[H])C |&1:1,3,6,10,12,15,17,18,20,33,35,r|
InChIKey
RFDAIACWWDREDC-NSPZZGDONA-N
乙二醇化学百科
基本信息
物化性质
安全信息
生产及用途
甘氨胆酸可用作去氢胆酸的中间体,组要用于实验室有机合成和化工医药研发过程,还可用于生化研究; 脂酶加速剂;阴离子去除剂,用于蛋白质的溶解。制备细菌培养基(肠道细菌培养与分离)。Glycocholic acid (Cholylglycine, Glycocholate) 是一种天然的次级胆汁酸,参与脂肪的乳化。
Glycocholic acid (GC) increases the cytotoxicity of epirubicin, significantly increases the intracellular accumulation of epirubicin in Caco-2 cells and the absorption of epirubicin in rat small intestine, and intensified epirubicin-induced apoptosis. Glycocholic acid and epirubicin significantly reduce mRNA expression levels of human intestinal MDR1, MDR-associated protein (MRP)1, and MRP2; downregulate the MDR1 promoter region; suppress the mRNA expression of Bcl-2; induce the mRNA expression of Bax; and significantly increase the Bax-to-Bcl-2 ratio and the mRNA levels of p53, caspase-9 and -3. A combination of anticancer drugs with Glycocholic acid can control MDR via a mechanism that involves modulating P-gp and MRPs as well as regulating apoptosis-related pathways.
化学性质 倍半水合物为结晶(5%乙醇)。熔点130℃。[α]23/D+30.8°(C7.5 95%乙醇);无水结晶熔点165-168℃。微溶于水,遇酸碱分解成甘氨酸和胆酸。用途 去氢胆酸的中间体。生产方法 可从胆汁或胆酸制取。
上下游产品
相关产品
|
|||||||||||||||||||||||||||||||||||||||||||||||